Skip to main content

Syneos Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

MORRISVILLE, N.C., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Michelle Keefe is scheduled to present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 a.m. EST. The Company will not be hosting investor meetings.

A live webcast of the event, along with a link to the presentation materials and archived replay of the presentation, will be available on the Company’s Investor Relations website at investor.syneoshealth.com.

About Syneos Health
Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization purpose-built to accelerate customer success. We lead with a product development mindset, strategically integrating clinical development, medical affairs and commercial capabilities to address modern market realities.

We bring together a talented team of professionals, who work across more than 110 countries, with a deep understanding of patient and physician behaviors and market dynamics. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health supports a diverse, equitable and inclusive culture that cares for colleagues, customers, patients, communities and the environment.

To learn more about how we are Shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.

Investor Relations Contact:
Ronnie Speight
Senior Vice President, Investor Relations
+1 919 745 2745
Investor.Relations@syneoshealth.com
               Press/Media Contact:
Gary Gatyas
Executive Director, External Communications
+1 908 763 3428
gary.gatyas@syneoshealth.com
   

Primary Logo

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.